6 results
Primary Objective:To demonstrate that the AlCath Flux eXtra Gold ablation catheter is non-inferior compared to historical datafrom the literature regarding the prevention of new subclinical cerebral thromboembolic lesions after PVI.Secondary…
Primary objective: To determine the efficacy of the combination of acalabrutinib and venetoclax without obinutuzumab (AV; Arm A), or with obinutuzumab (AVG; Arm B) compared with chemoimmunotherapy (fludarabine/cyclophosphamide/rituximab [FCR]/…
1) To determine whether advanced MRI techniques can detect active inflammatory Gd enhancing lesions. 2) To determine whether blood biomarkers are associated with the presence of enhancing brain lesions in MS. 3) To determine whether advanced MRI…
Primary objective• To evaluate efficacy of acalabrutinib/venetoclax (AV) in terms of undetectable minimal residual disease (uMRD) response in bone marrow (BM) after 26 cycles of treatment in patients with CLL previously treated with venetoclax and…
The aim is thereby to reduce the risk of serious infections and the need for regular CLL treatment.
Therapy:The investigational product, ACP-196, will be supplied as hardgelatin capsules for oral administration.Commercially available ibrutinib (IMBRUVICA®) will be used asthe reference therapy.Objectives: Primary Objective:To assess whether ACP-196…